BTIG Downgrades Imperva (IMPV) to Neutral
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BTIG downgraded Imperva (NYSE: IMPV) from Buy to Neutral and removed its price target. Analyst Joel P. Fishbein, Jr. sees balanced risk-reward.
"The stock is up ~23% since a report surfaced last week revealing potential acquirers, with bids due this week. We still think a deal could happen, but believe any premium is limited given where the stock is currently trading. On the flip side, our checks on the business itself are mixed, and turnover continues to be an issue in light of the sale process. We don’t think there’s risk to quarterly expectations (since the company drastically reduced FY revenue guidance by $50m/26%), but there is added risk in the stock if the process drags on (or if a deal fails to materialize altogether). Instead, we think it best for investors to move to the sidelines," said Fishbein.
Shares of Imperva closed at $53.71 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pivotal Research Downgrades Kroger (KR) to Hold
- Jefferies Cuts Price Target on Dollar General (DG) Following 3Q
- UPDATE: Oppenheimer Starts Shopify (SHOP) at Perform
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS View, Downgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!